Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,094 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Recruiting Not applicable Interventional

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

NCT06036810
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Shared Medical Decision Tool, Engaging Patients in Decision Making, Literacy Spanish Language
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 4:04 AM EDT
Terminated Phase 1 Interventional

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

NCT03203525
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Neoplasm
Interventions
Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pegylated Liposomal Doxorubicin Hydrochloride, Temsirolimus, Tumor Treating Fields Therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 14, 2026, 4:04 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Houston Independent School District (HISD) Yoga Evaluation

NCT02606591
View directory record Official record
Conditions
Health and Wellness
Interventions
Electroencephalograph, Cognitive Tests, Hair Sample
Procedure · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
8 Years to 11 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 14, 2026, 4:04 AM EDT
Terminated Phase 2 Interventional Results available

Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia

NCT03564678
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Hyperbilirubinemia
Interventions
Levocarnitine, Vitamin B Complex
Dietary Supplement · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 14, 2026, 4:04 AM EDT
Terminated Phase 4 Interventional Results available

Anderson Circulating Tumor Cell Burden (CTCB) Study

NCT00819832
View directory record Official record
Conditions
Cancer, Spinal Disease, Vertebral Compression Fractures
Interventions
Kyphoplasty, Vertebroplasty, Cavity SpineWand
Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 14, 2026, 4:04 AM EDT
Active, not recruiting Not applicable Interventional

Meditation Therapy in Improving Anxiety and Depression in Cancer Patients With Psychosocial Distress

NCT02988271
View directory record Official record
Conditions
Anxiety, Depression, Malignant Neoplasm
Interventions
Interview, Meditation Therapy, Quality-of-Life Assessment, Supportive Care
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 4:04 AM EDT
Active, not recruiting Early Phase 1 Interventional

An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients

NCT06635434
View directory record Official record
Conditions
Pain, Pediatric Cancer
Interventions
AR Pain assessment
Device
Lead sponsor
ALTality, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 14, 2026, 4:04 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

NCT05704634
View directory record Official record
Conditions
Lung Cancer
Interventions
Cemiplimab, Kevzara (Sarilumab)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 4:04 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

IGNITE-TX Phase III: (Identifying Individuals for Genetic Testing & Treatment) Intervention

NCT07318363
View directory record Official record
Conditions
Communication, Informed Decision-making
Interventions
IGNITE-TX program, Genetic Counseling and Testing
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 4:04 AM EDT
Terminated Phase 2 Interventional Results available

A Study of the HSP90 Inhibitor AUY922

NCT01485536
View directory record Official record
Conditions
Lymphoma
Interventions
AUY922
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 14, 2026, 4:04 AM EDT
Recruiting Phase 1 Interventional

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

NCT06769490
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Ziftomenib, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 4:04 AM EDT
Withdrawn Phase 3 Interventional

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

NCT05100160
View directory record Official record
Conditions
Thoracic, Pulmonary Disease
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 14, 2026, 4:04 AM EDT
Completed No phase listed Observational

Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients

NCT00352391
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
Assessments
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
3
States / cities
Fort Gordon, Georgia • Johnstown, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 14, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

ACTolog in Patients With Solid Cancers

NCT02876510
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
Fludarabine, Cyclophosphamide, IMA101 product, Recombinant human interleukin-2, IMADetect, Atezolizumab
Drug · Biological · Diagnostic Test
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 14, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

NCT01664910
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine Hydrochloride, Fludarabine Phosphate, Inotuzumab Ozogamicin, Methotrexate, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 14, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

NCT00429182
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Thiotepa, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 14, 2026, 4:04 AM EDT
Active, not recruiting Not applicable Interventional

TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning

NCT05743842
View directory record Official record
Conditions
Liver Cancer
Interventions
TriSalus™ TriNav™Infusion System, Angiogram, Y90-radioembolization procedure
Device · Diagnostic Test · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

NCT00535873
View directory record Official record
Conditions
Leukemia, CLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 14, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Phase II Study of Lorvotuzumab Mertansine

NCT02420873
View directory record Official record
Conditions
Leukemia
Interventions
Lorvotuzumab Mertansine (IMGN901)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 14, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03586661
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Progressive Disease, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Copanlisib, Niraparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 14, 2026, 4:04 AM EDT
Completed No phase listed Observational

Registry for Women Who Are At Risk Or May Have Lynch Syndrome

NCT00508573
View directory record Official record
Conditions
Hereditary Nonpolyposis Colorectal Cancer, Lynch Syndrome
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 14, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas

NCT00038441
View directory record Official record
Conditions
Glioma, Brain Neoplasms
Interventions
DTI-015
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 14, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

NCT00543842
View directory record Official record
Conditions
Rectal Cancer
Interventions
Bevacizumab, Capecitabine, Erlotinib, Radiation Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 14, 2026, 4:04 AM EDT
Recruiting Phase 2 Interventional

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT07269470
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Dasatinib, Ropeginterferon alfa-2b (P1101)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 4:04 AM EDT